Cancer Center Amsterdam
-
SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
van der Werf, I., Wojtuszkiewicz, A., Yao, H., Sciarrillo, R., Meggendorfer, M., Hutter, S., Walter, W., Janssen, J., Kern, W., Haferlach, C., Haferlach, T., Jansen, G., Kaspers, G. J. L., Groen, R., Ossenkoppele, G. & Cloos, J., Sept 2021, In: Leukemia. 35, 9, p. 2698-2702 5 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: The HOVON-SAKK-132 trial
Löwenberg, B., Pabst, T., Maertens, J., Gradowska, P., Biemond, B. J., Spertini, O., Vellenga, E., Griskevicius, L., Tick, L. W., Jongen-Lavrencic, M., Kooy, M. V. M., Vekemans, M.-C., van der Velden, W. J. F. M., Beverloo, B., Michaux, L., Graux, C., Deeren, D., Weerdt, O. D., Esser, J. W. J. V. & Klein, M. B. S. K. & 26 others, , 23 Feb 2021, In: Blood advances. 5, 4, p. 1110-1121 12 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds
Janssen, J., Löwenberg, B., Manz, M., Bargetzi, M., Biemond, B., von dem Borne, P., Breems, D., Brouwer, R., Chalandon, Y., Deeren, D., Efthymiou, A., Gjertsen, B.-T., Graux, C., Gregor, M., Heim, D., Hess, U., Hoogendoorn, M., Jaspers, A., Jie, A. & Jongen-Lavrencic, M. & 26 others, , 2 Feb 2021, In: Cancers. 13, 4, p. 1-11 11 p., 672.Research output: Contribution to journal › Article* › Academic › peer-review
- All publications